- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01967485
Text Messaging Adherence to Stimulant Medication
February 22, 2017 updated by: Mai Uchida, Massachusetts General Hospital
The purpose of this study is to determine if an individualized text messaging intervention for the parents of children with Attention Deficit/Hyperactivity Disorder is effective in improving medication adherence and disease management.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female children ages 6-17 years
- A diagnosis of ADHD (inattentive, hyperactive/impulsive, or combined type) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) based on clinical assessment and supported by a Clinical Global Impression- ADHD (CGI-ADHD) Severity Score of at least 4 (Moderately Ill)
- Has a parent in possession of a cellular phone with text messaging capabilities and is interested in and willing to receive planned text messages
- Has never been treated with stimulant medication, or has begun treatment with stimulant medication within three months of study enrollment.
Exclusion Criteria:
- Any serious, unstable, chronic medical condition, per clinician assessment
- Cardiovascular disease
- Current or past history of seizures
- Treatment with stimulant medication beyond three months prior to enrollment
- Pregnant or nursing females
- Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild
- Unstable psychiatric illness other than ADHD, including, but not limited to: Autism, Bipolar Disorder, Psychosis, Major Depressive Disorder, Anorexia, Bulimia, Post-Traumatic Stress Disorder and Anxiety Disorders
- History of multiple adverse drug reactions
- Presence of suicidal risk, or homicidality
- Unwilling/unable to comply with study procedures
- Poor command of the English language
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Text Messaging
Text messaging to the parents of children.
Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
|
Text messages will be sent to the parents of children enrolled in the study.
Children will receive stimulant treatment for ADHD.
|
|
Active Comparator: No Text Messaging
Children will receive open treatment for ADHD with stimulant medication.
This group will not get the text messaging intervention, but will receive treatment as usual.
|
Children will receive stimulant treatment for ADHD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication Adherence
Time Frame: Six Months
|
Adherence to the individualized medication regimen
|
Six Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mai Uchida, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
October 18, 2013
First Submitted That Met QC Criteria
October 22, 2013
First Posted (Estimate)
October 23, 2013
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 22, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-P-002161
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
King's College LondonActive, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder SymptomsUnited Kingdom
-
Cingulate TherapeuticsSuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcCompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Qbtech ABEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)United States
-
University of Texas at AustinRecruitingAttention Deficit Hyperactivity DisorderUnited States
-
Rutgers, The State University of New JerseyNational Institute of Mental Health (NIMH); Louisiana State University Health...Recruiting
-
Tongren Hongxin Kangxin Traditional Chinese Medicine...CompletedAttention Deficit Hyperactivity DisorderChina
-
Aytu BioPharma, Inc.Premier Research Group plcWithdrawnAttention Deficit Hyperactivity DisorderUnited States
-
Universidade do Sul de Santa CatarinaAssociação Brasileira de Cannabis MedicinalRecruitingAttention-Deficit/Hyperactivity Disorder (ADHD)Brazil
Clinical Trials on Text- Messaging
-
University of Colorado, DenverNational Institute of Mental Health (NIMH)CompletedHIV InfectionsUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCOVID-19United States
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
University of RochesterCompleted
-
University of MichiganCompletedStroke | Hypertension
-
University of Nebraska LincolnThe Methodist Hospital Research InstituteCompletedDiabetes Mellitus, Type 2United States
-
China National Center for Cardiovascular DiseasesCompleted
-
University of MichiganCompletedStroke | HypertensionUnited States
-
The Miriam HospitalCompletedHIV | Adherence | RetentionUnited States